In the KEYNOTE-054 trial, patients with high-risk stage III melanoma derived benefit from pembrolizumab regardless of PD-L1 status, and this marker was not reported at all in KEYNOTE-716 [32]. This evidence concerns the gene CD274 and melanoma.